Aktuellt
SENASTE
Redeye provides its initial take on Surgical Science’s Q2 2024 report, which featured a notable sequential recovery after the company’s weak Q1. We judge that positives from the report include sales aligning with our expectations. Notable negatives include softer-than-expected profitability, mainly resulting from revenue mix leading to lower-than-expected gross margins. We expect stronger growth and profitability in H2 2024e.
LÄS MER
